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http:WHAT THIS PAPER ADDS
The present study describes experience of thrombus management with stentgraft. This technique can reduce
mortality and morbidity associated with conventional surgery. The impact of morphological criteria on the
choice of suitable patients for intervention is analyzed.Background: Optimal management of aorta mural thrombus (AMT) continues to be controversial. The aim of this
study was to describe the management of AMT in the thoracic aorta with either conservative or stentgraft
treatment and to analyze the role of morphological characteristics of thrombus in the selection of suitable
candidates for intervention.
Methods: A retrospective review was conducted of all patients admitted for thoracic AMT. Clinical data,
treatment used, and outcomes were recorded. Patients were divided in two groups according to the treatment
used: either conservative or stentgraft. Morphological features of thrombus, including size, sessile or
pedunculated aspect and mobility, were compared between the two groups.
Results: From January 2006 to March 2013, 13 consecutive patients (nine male, mean age 53, range 37e76) were
admitted for symptomatic (n ¼ 8) or asymptomatic AMT (n ¼ 5). All patients received unfractionated heparin.
Management of primary aortic thrombus required stentgraft in seven patients, aortic thrombectomy in one, and
anticoagulation therapy alone in ﬁve. Indications for intervention were recurrent embolism (n ¼ 4), occurrence
of embolism under heparin (n ¼ 1), or persistent thrombus (n ¼ 2). Endovascular exclusion of AMT was
successful in all cases, with no complications or deaths at 30 days and no recurrence at midterm. Analysis of the
morphological features of the thrombus identiﬁed solely the high degree mobility as associated with adverse
outcome (p ¼ .048).
Conclusion: In our experience, stentgraft exclusion of AMT is an effective approach. Systematic evaluation of
thrombus mobility by a real-time imaging study can be helpful to better deﬁne the indications for radical
treatment of the aortic lesion.
 2013 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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The aortic wall is recognized as a potential cause of systemic
emboli.1,2 These embolic syndromes from the aorta include
diverse entities varying from thrombi in apparently normal
aortas to those found in complicated atherosclerotic pla-
ques.3 Until now, reports in the literature have mainly
mentioned aortic thrombi associated with diffuse athero-
sclerosis, which are well-known as protruding atheroma or
aortic debris.4e6 Aortic mural thrombus (AMT) or primary
aortic thrombus characterized by sessile or pedunculated
aortic thrombi that develop in the absence of pre-existingrresponding author. M. Bouﬁ, Department of Vascular Surgery,
ity Hospital Nord, Chemin des Bourrelly, 13915 Marseille Cedex 20,
.
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//dx.doi.org/10.1016/j.ejvs.2013.11.014aortic disease is a less well-described entity. The natural
history, prognosis, and management of AMT remain unclear
and no long-term follow-up is available. Therapeutic
methods differ between those in favour of medical treat-
ment with systemic anticoagulation,7e9 and those in favour
of an open surgical option.10,11 More recently, a few pub-
lished case reports12e22 have advocated endovascular
management with stentgraft exclusion as a safe and mini-
mally invasive option compared with open procedures. This
raises questions concerning the indications for primary
aortic lesion treatment.
In order to select candidates for primary aortic surgery,
certain factors have been identiﬁed in the literature as
predictors of adverse outcome.23 The part played by
thrombus morphology in the choice between conservative
and surgical management is controversial. However, no
studies analyzed clearly the criteria related to the degree of
thrombus mobility.
336 M. Bouﬁ et al.The present study reports our experience of thoracic
AMT management either with solely anticoagulation ther-
apy or stentgraft deployment and analyzes the role of
morphological characteristics of the thrombus in the deci-
sion for primary aortic lesion treatment.
MATERIALS AND METHODS
From January 2006 to March 2013, we retrospectively
reviewed all patients who were admitted to our department
with thoracic aortic mural thrombi. The diagnosis was
determined by the clinical contexts of embolic events and
imaging criteria.
A thoraco-abdominal computed tomography angiography
(CTA) was systematically performed as part of the etiolog-
ical diagnosis of arterial embolism and therefore repre-
sented the ﬁrst imaging modality revealing the AMT.
Transoesophageal echocardiography (TEE) was indicated in
cases of persistent thrombus, deﬁned as a stable thrombus
after more than 15 days of anticoagulation, or recurrent
embolism. It was used as a complementary method to
evaluate the ﬂoating aspect of the aortic lesion which was
classiﬁed as highly or minorly mobile, thus helping to deﬁne
therapeutic strategies.
Highly mobile thrombus was deﬁned as a thrombus with
free edge moving on either side of an axis perpendicular to
the implantation site during the cardiac cycle visualized in
the two-dimensional view, and in an oscillatory fashion in
the M-mode. For the other cases the thrombus was
considered as minorly mobile. Patients with aortic
thrombus associated with underlying aortic disease (diffuse
atherosclerotic disease including protruding atheroma,
penetrating aortic ulcer or aneurysm) as well as aortic mural
tumour were excluded.
Medical records of patients were reviewed for: de-
mographic data, medical co-morbidities, symptoms on
admission, imaging studies, morphological characteristics of
thrombus including size, pedunculated or sessile aspect and
mobility, outcomes after anticoagulation therapy, in-
dications for stentgrafts, procedural details and ultimate
outcomes after medical or endovascular treatment.
In our practice, all patients admitted with the diagnosis of
AMT received initial unfractionated heparin for 2 weeks.
The distal embolic events were managed with embolec-
tomy, except for renal embolism associated with paren-
chyma infarction which was conservatively treated with
heparin.Indication for primary aortic lesion treatment
Stentgraft treatment was reserved for patients with failed
anticoagulation therapy: ﬁrstly for occurrence of embolic
event in initially asymptomatic patients on heparin; sec-
ondly for recurrence of an embolization episode in a
symptomatic patient despite full anticoagulation; and
thirdly for persistent thrombus despite more than 15 days
of medical treatment with high degree of mobility on TEE.
Patients who were considered as high risk for aortic
surgery and those with regressive thrombus, whethersymptomatic or asymptomatic, were given only anti-
coagulation therapy.Stentgraft procedure
The procedures were performed in the operating theatre
under general anaesthesia. A femoral or iliac access was
used to introduce the aortic stentgraft. Left brachial access
was generally used for the contrast injection, to avoid
crossing the mobile thrombus. Manipulation of the guide-
wire in the thoracic aorta was limited. Thoracic aortic
stentgrafts were used to completely exclude the thrombus.
The choice of device in terms of length and diameter was
made by an oversizing of less than 10% of the measured
luminal diameter and the length of the aortic thrombus plus
2 cm above and below the implantation site of thrombus.
TEE was used intra-operatively to ensure safe advance-
ment and positioning of the stentgraft. Remodelling was
not used after the deployment of the stentgraft. If the
proximal landing zone of the stentgraft was located prox-
imal to the left subclavian artery, a preliminary debranching
of the supra-aortic vessels was performed.Follow-up
After discharge, the follow-up protocol comprised regular
consultations at 6 and 12 months and then yearly, with a
duplex scan of the peripheral and/or visceral arteries and
aortic CTA. Outcomes, including recurrent embolism or
aortic thrombus and death, were recorded.Statistical analysis
Non-parametric ManneWhitney test was performed to
compare the mean size of thrombus between the stentgraft
and conservative group, whereas the Fischer exacts tests
were used to compare frequencies. A p value below 0.05
was considered signiﬁcant.
RESULTS
During the study period, 13 patients were admitted for AMT
of thoracic aorta (nine male, mean age 53 years, range 37e
76 years).Clinical presentation and etiological factors
At the time of admission eight patients were symptomatic
with arterial embolism, involving lower extremity in four,
upper extremity in one, superior mesenteric artery in one,
vertebral artery in one, and in the remaining patient mul-
tiple emboli (lower extremity, superior mesenteric artery
and renal artery). For the other ﬁve patients the aortic
thrombus was revealed fortuitously in staging CTA for se-
vere asthma in one, trauma in one, ischemic stroke related
to carotid stenosis in one, and pulmonary neoplasm in two.
Predisposing factors to thrombus formation included:
thrombophilia n ¼ 2 (protein S deﬁciency in one case and
hyperhomocysteinaemia in the other), inﬂammatory bowel
disease n ¼ 1, trauma n ¼ 1, steroid therapy n ¼ 1,
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or several cardiovascular risk factors (Table 1).
Treatment
All patients, whether symptomatic or asymptomatic, were
given anticoagulation therapy with unfractionated heparin
for at least 15 days. Four patients had recurrence of
embolization (peripheral emboli in two cases, cerebral
emboli in one, and mesenteric emboli in one) and one had a
new embolic event despite full anticoagulation (Table 2).
Management of the arterial embolism required surgical
embolectomy in six patients. Patient no. 11, initially
admitted for acute limb ischemia, was contraindicated for
surgical treatment, and therefore treated conservatively.
Histological examination of the thrombus revealed a ﬁbri-
nous clot in all cases.
Management of the primary aortic thrombus required
stentgraft deployment in seven patients and a transaortic
thrombectomy of the thoracic aorta and the visceral ar-
teries in one patient, for whom the lesion was anatomically
unfavourable for endovascular treatment (Table 2).
Indications for aortic lesion treatment were the recur-
rence of the embolic event in four, the occurrence of renal
embolism despite full anticoagulation in one, and the
persistence of a highly mobile thrombus after more than 2
weeks of systemic anticoagulation in two. For the other ﬁve
patients the primary aortic thrombus was medically treated
with warfarin for 6 months (Table 2). The choice of con-
servative treatment was based on the low degree of
mobility for the initially persistent thrombus (n ¼ 2) and the
favourable outcome after systemic anticoagulation with
either regression of the mobile part (n ¼ 2) or complete
resolution of the thrombus (n ¼ 1).
For the endovascular group, emergency procedures
were performed within 24 hours of diagnosis in instances
of recurrence or occurrence of embolism. Intra-operative
TEE was used in four patients. The stentgrafts deployed
were Zenith TX2 (William Cook Europe, Bjaeverskov
Denmark) (n ¼ 5) and Valiant Captivia (Medtronic
Vascular, Santa Rosa, CA, USA) (n ¼ 2). Only one endo-
prosthesis of 100 to 115 mm length was used per patient.Table 1. Demographic data of the study population.
Patient
no.
Age
(y)
Gender
1 61 F
2 65 M
3 51 M
4 53 M
5 38 M
6 37 F
7 38 F
8 76 M
9 53 M
10 55 M
11 45 M
12 75 M
13 43 F
DM ¼ diabetes mellitus; HT ¼ hypertension; y ¼ years.For two patients with thrombus in the distal arch, trans-
position of the left subclavian artery was required prior to
the exclusion of the aortic lesion. No patient had spinal
catheter drainage during the procedure. No intra- or post-
operative complications occurred and no death was noted
at 30 days. All the patients were discharged with single
antiplatelet therapy (aspirin or clopidogrel) except the
patient with trauma, who had a vena cava thrombus, and
the two patients with thrombophilia, who were switched
to warfarin.Analysis of thrombus characteristics
CTA revealed a sessile thrombus in four cases in the sten-
tgraft group and three cases in the conservative group
(Fig. 1A, B). The thrombus was located in the aortic arch in
three patients, in the descending thoracic aorta in six, and
in the thoraco-abdominal aorta in four with an extension to
the visceral arteries in one (Fig. 2). The mean length of
aortic thrombus was 29 mm (range 15e80 mm) in the
stentgraft group and 26 mm (12e35 mm) in the conser-
vative group. A complementary TEE was performed pre-
operatively in six cases revealing a highly mobile
thrombus in four and a minorly mobile thrombus (Table 2).
Analysis of the different criteria showed a signiﬁcantly
higher rate of highly mobile thrombus in the stentgraft
group compared with the conservative group (p ¼ .048).
Thus, high mobility can be considered as a factor associated
with anticoagulation therapy failure. However, the size was
similar in the two groups (p ¼ .37) as were the sessile or
pedunculated aspects of thrombus (p ¼ 1).Clinical and CTA follow-up
After a mean follow-up of 32 months (range 2e78 months)
for the patients treated with stentgraft, control ﬁndings
showed satisfactory outcomes, with neither AMT recur-
rence nor re-embolization (Table 2; Fig. 1C).
For the medical treatment group, the mean follow-up
was 15 months (range 5e25 months). Outcomes were
favourable, except for the patient with gastric cancer who
died at 25 months secondary to neoplasm (Table 2).Predisposing factors Cardiovascular
risk factors
e DM, HT
e HT
e Smoking
e DM
Thoracic trauma e
e Smoking
Protein S deﬁciency Smoking
Steroid therapy e
Gastric malignancy e
Hyperhomocysteinaemia e
Crohn’s e
e HT
Pulmonary cancer Smoking
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338 M. Bouﬁ et al.DISCUSSION
Emboli from apparently normal aortas are rare events. The
pathophysiological mechanisms of locally formed thrombi in
the aortic wall remain poorly deﬁned. Hypercoagulability
and primary endothelial disease have been proposed as the
most important aetiological factors for AMT formation.7 In
our study, thrombophilia factors were found in two pa-
tients; however, 62% of patients had cardiovascular risk
factors, as in Reber’s series,24 suggesting that AMT forma-
tion is primarily a localized problem of vulnerable aortic
wall lesions which are a focal point for local thromboses.
Moreover, in practice it is difﬁcult to exclude atherosclerosis
as the aetiology of these lesions. AMT can thus be consid-
ered as a variant of atherosclerosis, occurring in young
patients and characterized by pure and local clot formation,
even if no atherosclerotic plaques is found on the imaging
studies. This hypothesis is also supported by Laperche
et al.25 in a TEE analysis of patients with aortic arch mobile
thrombus showing a small atherosclerotic plaque less than
4 mm at the insertion site of thrombus in 64% of cases and
a normal adjacent aortic wall in 74% of cases.
Different therapeutic options have been suggested for
the management of such lesions, including medical treat-
ment with anticoagulation therapy, surgical treatment,
thrombolysis, and, more recently, endovascular exclusion
with a stentgraft, but no clear consensus has been adopted.
Nevertheless, given the high risks of recurrence or persis-
tence of thrombus on the one hand, and on the other hand
a tendency to a high rate of complications and limb loss
associated with medical treatment noted in the meta-
analysis of Fayad et al.,23 surgical management of AMT
appear to be favoured.
Indeed, the rate of recurrence after heparin treatment is
33% in the series of Rossi et al.,11 25.7% in the meta-
analysis of Fayad et al.,23 and in our series 39% (n ¼ 5) of
patients presented with either a recurrence of the embo-
lization or a new embolic event.
Considering the high perioperative mortality and
morbidity related to conventional surgery, Fayad et al.23
failed to show a signiﬁcant difference between the anti-
coagulation group and the primary aortic surgery group.
However, with a less invasive technique such as stentgraft
treatment, it may be possible to demonstrate the beneﬁt.
In our study primary aortic thrombus was managed ac-
cording to criteria related to the patient’s co-morbidities
and to the lesions - outcomes after anticoagulation ther-
apy and mobility on TEE. Endovascular treatment remains
our preferred approach. Surgical transaortic thrombectomy
is reserved for instances of unfavourable stentgraft
anatomy.
Since the ﬁrst description of stentgraft use by Criado
et al.,12 few other case reports of endovascular exclusion of
mobile thoracic thrombi have been published. So far, our
analysis of the literature has identiﬁed 10 cases of sten-
tgraft implantation for AMT exclusion.12e22 In eight cases,
the thrombus was located in the distal arch or the
descending thoracic aorta. For the remaining two patients
Figure 1. A 76 year-old-patient with asymptomatic thrombus in the
aortic isthmus. (A) Sagittal view of CT scan shows a sessile
thrombus originating 2 cm below the left subclavian artery. (B)
Axial view shows the ﬂoating aspect of the thrombus. (C) Axial
view of the post-operative CT scan shows no recurrence 32 months
after stentgraft implantation.
Figure 2. Schematic representation of thrombus location and
aspect in the different segments of the thoracic aorta.
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treatment consisted of a hybrid technique for one and the
VORTEC technique for the other.19,21 All these cases were
successfully treated with no deaths or major complications.
The main concern with this technique is the risk of
thrombus dislodgment either during navigation of the aorta
by the guide-wire and/or the stentgraft deployment. In our
series, several measures were adopted to prevent the risk
of distal embolization. Firstly, the procedure was performed
without interrupting systemic anticoagulation. Secondly,
manipulation of wires and catheters in the aorta were
minimized. Thirdly, an appropriate stentgraft was chosen in
terms of diameter (oversizing <10%) and length making it
possible to cover the aorta at least 2 cm above and below
the implantation site of the thrombus.
Data from the literature and in our series showed no
arterial embolism during the procedures. However, as rec-
ommended by Fueglistaler et al.,17 we systematically per-
formed visceral angiography at the end of the procedure to
detect any potential embolization.
In the aforementioned meta-analysis,23 the authors
identiﬁed predictive factors for the recurrence of embolic
event in order to select suitable surgical candidates. These
factors were related to clinical presentation (stroke), loca-
tion of thrombus (ascending aorta or aortic arch), and
atherosclerotic status of the aortic wall (mild
atherosclerosis).
The characteristics of the thrombus in terms of mobility
have been identiﬁed by others25e27 as a determining factor
340 M. Bouﬁ et al.for primary surgical treatment. However, in these reports
the mobility was not clearly deﬁned. In our study TEE was
used as an imaging modality to provide dynamic visualiza-
tion of thrombus which was classiﬁed as highly or minorly
mobile. Analysis of TEE ﬁndings showed that highly mobile
thrombus was signiﬁcantly associated with adverse
outcome. However, as in the meta-analysis of Fayad et al.,23
the size and the pedunculated or sessile nature of the
thrombus were similar in both groups.
With the advent of the endovascular approach, the
indication for treating aortic wall thrombotic lesions should
also be reconsidered, given the high risk of embolism with
these lesions on the one hand, and the less invasive nature
of the procedure on the other. We fully acknowledge that
ﬁnal conclusions cannot be drawn from the small number of
patients in our series. However, in our experience, excluding
thoracic aortic thrombi with stentgraft does appear to be an
efﬁcient approach with minimal risk of peri-operative
emboli or recurrence of the thrombi. TEE was useful in
deciding between the conservative and the endovascular
options. However, this technique is limited by the poor
visualization of the junction between the ascending aorta
and the aortic arch as a result of interposition of the
trachea.
We believe that systematic evaluation of thrombus
mobility provided by a real-time dynamic imaging, notably
TEE, is necessary to identify patients with high risk of em-
bolism. Such patients can be considered as good candidates
for early endovascular treatment given the potential failure
risk of a purely conservative approach.CONCLUSION
AMT is a rare event with serious potential consequences.
Management of the primary aortic lesion with anti-
coagulation therapy alone poses a risk of recurrence or
occurrence of an embolic event. In our experience, sten-
tgraft exclusion seems to be a safe approach. Systematic
evaluation of thrombus mobility by real-time imaging
studies can be useful to select patients at risk of embolism
and to better deﬁne indications for radical treatment of the
aortic lesion.CONFLICT OF INTEREST
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